Appleton Sarah L, Reynolds Amy C, Gill Tiffany K, Melaku Yohannes Adama, Adams Robert J
Flinders Health and Medical Research Institute - Sleep Health (Adelaide Institute for Sleep Health), College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
The Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
Nat Sci Sleep. 2022 Apr 21;14:775-790. doi: 10.2147/NSS.S359437. eCollection 2022.
Estimating insomnia prevalence in epidemiological studies is hampered by variability in definitions and interpretation of criteria. We addressed the absence of a population-based estimate of insomnia in Australia using the widely accepted contemporary International Classification of Sleep Disorders (ICSD-3) criteria, which includes sleep opportunity, and has not been applied in studies to date. Consistent use of these criteria across epidemiological studies, however, requires evidence of the clinical utility of a sleep opportunity criterion for targeting strategies.
A cross-sectional national on-line survey (2019 Sleep Health Foundation Insomnia Survey) of Australian adults (18-90 years, n = 2044) was conducted. Chronic insomnia was defined as sleep symptoms and daytime impairment experienced ≥3 times per week, and present for ≥3 months, with adequate sleep opportunity (time in bed (TIB) ≥7.5 hrs). Self-rated general health (SF-1) and ever diagnosed health conditions (including sleep disorders) were assessed.
Chronic difficulties initiating and maintaining sleep and daytime symptoms (n = 788) were more common in females (41.5%) than males (35.3%), p = 0.004. Excluding participants reporting frequent pain causing sleep disruption and TIB <7.5 hrs generated an insomnia disorder estimate of 25.2% (95% CI: 22.5-28.2) in females and 21.1% (18.4-23.9) in males [23.2% (21.2-25.2) overall]. This compares with 8.6% (7.3-10.0) with insomnia symptoms and TIB <7.5 hrs and 7.5% (6.4-8.7%) ever diagnosed with insomnia. Insomnia symptom groups with TIB <7.5 and ≥7.5 hours demonstrated similar odds of reporting fair/poor health [odds ratio (OR): 3.2 (95% CI: 2.1-4.8) and 2.9 (95% CI: 2.2-3.9) respectively], ≥1 mental health condition, ≥1 airway disease, and multimorbidity.
Adults with significant sleep and daytime symptomatology and TIB <7.5 hrs did not differ clinically from those with insomnia disorder. Consideration of criteria, particularly adequate sleep opportunity, is required to consistently identify insomnia, and establish health correlates in future epidemiological studies. Further evaluation of the clinical utility of the sleep opportunity criterion is also required.
在流行病学研究中,失眠患病率的估算因标准定义和解读的差异而受到阻碍。我们采用广泛认可的当代《国际睡眠障碍分类》(ICSD - 3)标准,解决了澳大利亚缺乏基于人群的失眠患病率估算这一问题,该标准纳入了睡眠时间,且此前尚未在相关研究中应用。然而,在流行病学研究中一致使用这些标准,需要有证据证明睡眠时间标准对针对性策略具有临床实用性。
对澳大利亚成年人(18 - 90岁,n = 2044)进行了一项全国性横断面在线调查(2019年睡眠健康基金会失眠调查)。慢性失眠被定义为睡眠症状和日间功能损害每周出现≥3次,且持续≥3个月,同时具备充足的睡眠时间(卧床时间(TIB)≥7.5小时)。对自我评定的总体健康状况(SF - 1)和既往诊断的健康状况(包括睡眠障碍)进行了评估。
慢性入睡困难、维持睡眠困难及日间症状(n = 788)在女性(41.5%)中比男性(35.3%)更常见,p = 0.004。排除报告频繁疼痛导致睡眠中断以及TIB < 7.5小时的参与者后,女性失眠障碍估计患病率为25.2%(95%可信区间:22.5 - 28.2),男性为21.1%(18.4 - 23.9)[总体为23.2%(21.2 - 25.2)]。相比之下,有失眠症状且TIB < 7.5小时的患病率为8.6%(7.3 - 10.0),曾被诊断为失眠的患病率为7.5%(6.4 - 8.7%)。TIB < 7.5小时和≥7.5小时的失眠症状组报告健康状况一般/较差、≥1种心理健康状况、≥1种气道疾病以及多种疾病并存的几率相似[优势比(OR):分别为3.2(95%可信区间:2.1 - 4.8)和2.9(95%可信区间:2.2 - 3.9)]。
有明显睡眠及日间症状且TIB < 7.5小时的成年人在临床上与患有失眠障碍的成年人并无差异。在未来的流行病学研究中,需要考虑相关标准,特别是充足的睡眠时间,以一致地识别失眠并确定其与健康的关联。还需要进一步评估睡眠时间标准的临床实用性。